Detailed information for compound 406534

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 2258.39 | Formula: C109H140N20O33
  • H donors: 24 H acceptors: 27 LogP: -1.96 Rotable bonds: 53
    Rule of 5 violations (Lipinski): 4
  • SMILES: O=C(NC(C(=O)NCCCCC1NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CNC(=O)[C@H](NC1=O)CCCN=C(N)N)CCC(=O)NCCCC[C@H]1NC(=O)[C@H](Cc2ccc(cc2)O)NC(=O)[C@@H](CC(=O)O)NC(=O)CNC(=O)[C@H](NC1=O)CCCN=C(N)N)CCO[C@@H]([C@H](c1ccccc1)NC(=O)c1ccccc1)C(=O)OC1C[C@@]2(O)[C@@H](OC(=O)c3ccccc3)C3[C@@](C(=O)[C@@H](C(=C1C)C2(C)C)OC(=O)C)(C)[C@@H](O)CC1[C@]3(CO1)OC(=O)C
  • InChi: 1S/C109H140N20O33/c1-57-76(53-109(156)91(161-102(154)64-26-14-9-15-27-64)89-107(6,77(134)52-78-108(89,56-158-78)162-59(3)131)90(143)87(159-58(2)130)85(57)106(109,4)5)160-103(155)88(86(62-22-10-7-11-23-62)129-92(144)63-24-12-8-13-25-63)157-47-42-80(136)120-71(93(145)115-44-19-17-29-70-97(149)124-68(31-21-46-117-105(112)113)95(147)119-55-82(138)122-75(51-84(141)142)101(153)128-73(99(151)126-70)49-61-34-38-66(133)39-35-61)40-41-79(135)114-43-18-16-28-69-96(148)123-67(30-20-45-116-104(110)111)94(146)118-54-81(137)121-74(50-83(139)140)100(152)127-72(98(150)125-69)48-60-32-36-65(132)37-33-60/h7-15,22-27,32-39,67-78,86-89,91,132-134,156H,16-21,28-31,40-56H2,1-6H3,(H,114,135)(H,115,145)(H,118,146)(H,119,147)(H,120,136)(H,121,137)(H,122,138)(H,123,148)(H,124,149)(H,125,150)(H,126,151)(H,127,152)(H,128,153)(H,129,144)(H,139,140)(H,141,142)(H4,110,111,116)(H4,112,113,117)/t67-,68-,69-,70?,71?,72+,73+,74-,75-,76?,77+,78?,86+,87-,88+,89?,91+,107-,108+,109-/m1/s1
  • InChiKey: YUHVDRZERRVMDC-XLKUZTQTSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) Starlite/ChEMBL References
Homo sapiens integrin, alpha V References

Predicted pathogen targets for this compound

By orthology
Species Potential target Known druggable target/s Ortholog Group
Schistosoma japonicum ko:K06476 integrin alpha 2B, putative Get druggable targets OG5_129341 All targets in OG5_129341
Schistosoma japonicum ko:K06464 integrin beta 2, putative Get druggable targets OG5_127959 All targets in OG5_127959
Schistosoma mansoni integrin alpha Get druggable targets OG5_129341 All targets in OG5_129341
Echinococcus granulosus integrin beta 2 Get druggable targets OG5_127959 All targets in OG5_127959
Echinococcus granulosus integrin alpha 3 Get druggable targets OG5_129341 All targets in OG5_129341
Echinococcus multilocularis integrin beta 2 Get druggable targets OG5_127959 All targets in OG5_127959
Echinococcus multilocularis integrin alpha 3 Get druggable targets OG5_129341 All targets in OG5_129341
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_129341 All targets in OG5_129341
Brugia malayi Integrin beta pat-3 precursor Get druggable targets OG5_127959 All targets in OG5_127959
Schistosoma japonicum Integrin beta-3 precursor, putative Get druggable targets OG5_127959 All targets in OG5_127959
Loa Loa (eye worm) integrin alpha pat-2 Get druggable targets OG5_129341 All targets in OG5_129341
Schistosoma mansoni integrin beta subunit Get druggable targets OG5_127959 All targets in OG5_127959
Loa Loa (eye worm) integrin beta-2 Get druggable targets OG5_127959 All targets in OG5_127959
Schistosoma japonicum IPR013513,Integrin alpha chain, C-terminal cytoplasmic region,domain-containing Get druggable targets OG5_129341 All targets in OG5_129341
Schistosoma japonicum Integrin beta-PS precursor, putative Get druggable targets OG5_127959 All targets in OG5_127959
Brugia malayi Integrin alpha pat-2 precursor Get druggable targets OG5_129341 All targets in OG5_129341
Loa Loa (eye worm) hypothetical protein Get druggable targets OG5_129341 All targets in OG5_129341
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus multilocularis integrin alpha ps integrin, alpha V 1002 aa 908 aa 22.6 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Schistosoma mansoni integrin beta subunit 0.0223 0.4242 0.1883
Giardia lamblia 70 kDa peptidylprolyl isomerase, putative 0.0387 1 0.5
Loa Loa (eye worm) hypothetical protein 0.0334 0.8132 0.8132
Leishmania major peptidylprolyl isomerase-like protein 0.0387 1 0.5
Plasmodium vivax 70 kDa peptidylprolyl isomerase, putative 0.0387 1 0.5
Trypanosoma brucei FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative 0.0387 1 0.5
Echinococcus granulosus peptidyl prolyl cis trans isomerase FKBP4 0.0387 1 1
Brugia malayi FKBP-type peptidyl-prolyl cis-trans isomerase-59, BmFKBP59 0.0387 1 1
Echinococcus multilocularis fk506 binding protein 0.0387 1 1
Loa Loa (eye worm) integrin beta-2 0.0378 0.97 0.97
Plasmodium falciparum peptidyl-prolyl cis-trans isomerase FKBP35 0.0387 1 0.5
Schistosoma mansoni immunophilin 0.0387 1 1
Brugia malayi Integrin alpha pat-2 precursor 0.0185 0.2906 0.182
Trypanosoma brucei peptidyl-prolyl cis-trans isomerase, putative 0.0387 1 0.5
Entamoeba histolytica peptidyl-prolyl cis-trans isomerase, FKBP-type, putative 0.0387 1 0.5
Echinococcus granulosus peptidyl prolyl cis trans isomerase FKBP1A 0.0387 1 1
Trypanosoma cruzi peptidyl-prolyl cis-trans isomerase, putative 0.0387 1 0.5
Schistosoma mansoni immunophilin 0.0387 1 1
Echinococcus granulosus peptidyl prolyl cis trans isomerase FKBP4 0.0334 0.8132 0.7829
Loa Loa (eye worm) FKBP5 protein 0.0387 1 1
Loa Loa (eye worm) FKBP-type peptidyl-prolyl cis-trans isomerase-12 0.0387 1 1
Loa Loa (eye worm) hypothetical protein 0.0145 0.1513 0.1513
Trypanosoma cruzi peptidyl-prolyl cis-trans isomerase, putative 0.0387 1 0.5
Trichomonas vaginalis immunophilin, putative 0.0387 1 0.5
Echinococcus multilocularis peptidyl prolyl cis trans isomerase FKBP4 0.0334 0.8132 0.7829
Mycobacterium ulcerans FK-506 binding protein, peptidyl-prolyl cis-trans isomerase 0.0387 1 0.5
Trichomonas vaginalis peptidylprolyl isomerase, putative 0.0387 1 0.5
Loa Loa (eye worm) hypothetical protein 0.014 0.1327 0.1327
Schistosoma mansoni immunophilin 0.0334 0.8132 0.7367
Echinococcus multilocularis integrin beta 2 0.028 0.6259 0.5653
Leishmania major fk506-binding protein 1-like protein 0.0387 1 0.5
Schistosoma mansoni immunophilin FK506 binding protein FKBP12 0.0387 1 1
Trichomonas vaginalis fk506-binding protein, putative 0.0387 1 0.5
Echinococcus granulosus integrin beta 2 0.028 0.6259 0.5653
Trichomonas vaginalis peptidylprolyl isomerase, putative 0.0387 1 0.5
Echinococcus multilocularis peptidyl prolyl cis trans isomerase FKBP4 0.0387 1 1
Trypanosoma cruzi FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative 0.0387 1 0.5
Treponema pallidum peptidyl-prolyl cis-trans isomerase, FKBP-type, 22 kDa (fklB) 0.0387 1 0.5
Entamoeba histolytica peptidyl-prolyl cis-trans isomerase, FKBP-type , putative 0.0387 1 0.5
Brugia malayi Integrin beta pat-3 precursor 0.0378 0.97 0.9654
Giardia lamblia FKBP-type peptidyl-prolyl cis-trans isomerase 0.0387 1 0.5
Trypanosoma cruzi FK506-binding protein (FKBP)-type peptidyl-prolyl isomerase, putative 0.0387 1 0.5
Loa Loa (eye worm) integrin alpha pat-2 0.0285 0.6416 0.6416

Activities

Activity type Activity value Assay description Source Reference
IC50 (functional) = 134 nM Inhibition of human metastatic breast cancer (MDA-MB-435) cell proliferation ChEMBL. 15715477
IC50 (functional) = 134 nM Inhibition of human metastatic breast cancer (MDA-MB-435) cell proliferation ChEMBL. 15715477
Radioactivity (functional) = 0.07 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.07 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.14 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.14 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.23 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.23 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.23 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.23 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.29 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.29 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.33 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.33 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.34 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.34 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.37 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.37 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.39 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.39 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.41 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.41 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.42 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.42 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.44 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.44 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.45 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.45 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.47 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.47 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.48 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.48 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.49 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.49 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.55 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.55 %ID/g Radioactivity uptake of compound was observed in pancreas of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.58 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.58 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.58 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.58 %ID/g Radioactivity uptake of compound was observed in muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.63 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.63 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.63 %ID/g Radioactivity uptake of compound was observed in blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.63 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.81 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.81 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.81 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.81 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.82 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.82 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.83 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.83 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.95 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.95 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.95 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.95 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.97 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.97 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.99 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 0.99 %ID/g Radioactivity uptake of compound was observed in heart of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.04 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.04 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.06 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.06 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.14 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.14 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.24 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.24 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.38 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.38 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.45 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.45 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.52 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.52 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.55 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.55 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.55 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.55 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.6 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.6 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.77 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.77 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.81 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.81 %ID/g Radioactivity uptake of compound was observed in bone of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.91 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 1.91 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.06 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.06 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.14 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.14 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.25 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.25 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.32 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.32 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.36 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.36 %ID/g Radioactivity uptake of compound was observed in lung of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.37 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.37 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.43 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.43 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.52 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.52 %ID/g Radioactivity uptake of compound was observed in intestine of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.53 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.53 %ID/g Radioactivity uptake of compound was observed in spleen of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.54 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.54 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.72 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 2.72 %ID/g Radioactivity uptake of compound was observed in tumor of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.01 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.01 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.02 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.02 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h block in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.08 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.08 %ID/g Radioactivity uptake of compound was observed in stomach of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.32 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.32 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.32 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.32 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.33 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.33 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.35 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.35 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.59 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.59 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 0.5 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.61 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 3.61 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 4.03 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 4.03 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 1 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 4.25 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 4.25 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 4.76 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 4.76 %ID/g Radioactivity uptake of compound was observed in tumor/muscle of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 5.53 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 5.53 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 5.66 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 5.66 %ID/g Radioactivity uptake of compound was observed in liver of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 6.51 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 6.51 %ID/g Radioactivity uptake of compound was observed in kidney of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 11.9 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 11.9 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 2 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 33.4 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477
Radioactivity (functional) = 33.4 %ID/g Radioactivity uptake of compound was observed in tumor/blood of MDA-MB-435 Xenograft model after i.v. Injection of 2 uCi of [125I]-E[c(RGDyK)]2-PTX conjugate at 4 h in mouse; (n=4) ChEMBL. 15715477

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.